Philadelphia Chromosome Positive (Ph+) (DBCOND0047040)

Identifiers

Synonyms

Philadelphia Chromosome Positive / Philadelphia Chromosome-Positive / Philadelphia Positive / Philadelphia positive (qualifier value)

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT03576547	Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia	Dexamethasone Ponatinib Rituximab Venetoclax	treatment	1 / 2	completed
NCT03698552	ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia	No drug interventions	treatment	1 / 2	recruiting
NCT03519984	EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia	Cytarabine SEphB4-HSA Vincristine	treatment	1	terminated
NCT04329325	Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Blinatumomab Dasatinib Dexamethasone Methotrexate	treatment	2	active_not_recruiting
NCT03233854	CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies	Cyclophosphamide Fludarabine	treatment	1	active_not_recruiting
NCT01190930	Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma	Asparaginase Escherichia coli Calcium Cyclophosphamide Cytarabine Dexamethasone Doxorubicin Leucovorin Levoleucovorin Mercaptopurine Methopterin Methotrexate Pegaspargase Sulfate ion Tioguanine Vincristine	treatment	3	active_not_recruiting
NCT01424982	Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia	Cortisone Cyclophosphamide Cytarabine Daunorubicin Dexamethasone Doxorubicin Methopterin Methotrexate Ponatinib Prednisone Rituximab Sulfate ion Vincristine	treatment	2	active_not_recruiting
NCT05007873	ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase	Cedazuridine Dasatinib Decitabine	treatment	2	recruiting
NCT03589729	Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers	Cladribine Cytarabine Dexrazoxane Gemtuzumab ozogamicin Idarubicin	supportive_care	2	recruiting
NCT03512405	Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia	Blinatumomab Muromonab Pembrolizumab	treatment	1 / 2	recruiting
NCT02997761	Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia	Blinatumomab Ibrutinib Muromonab	treatment	2	recruiting
NCT00390793	Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.	Cortisone Cyclophosphamide Cytarabine Dasatinib Daunorubicin Dexamethasone Doxorubicin Methopterin Methotrexate Prednisone Vincristine	treatment	2	completed
NCT01043874	Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response	Nilotinib	treatment	4	completed
NCT03241940	Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies	Cyclophosphamide Fludarabine	treatment	1	recruiting
NCT03263572	Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia	Blinatumomab Cytarabine Methopterin Methotrexate Muromonab Ponatinib	treatment	2	recruiting
NCT02458014	Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease	Blinatumomab Muromonab	treatment	2	active_not_recruiting
NCT01131325	Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations	Nilotinib	treatment	4	terminated
NCT06308588	Phase II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Asciminib Blinatumomab	treatment	2	recruiting
NCT01641107	Phase II Front-line Ponatinib in Adult Philadelphia+/BCR-ABL+ Acute Lymphoblastic Leukemia.	Ponatinib	treatment	2	completed
NCT02448095	Retrospective Evaluation of CML Patients in the National Compassionate Program	Ponatinib	Not Available	Not Available	terminated